Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer and SIRS-Lab to collaborate on sepsis research

Pfizer and SIRS-Lab to collaborate on sepsis research

25th November 2010

Pfizer is to enter into partnership with molecular diagnostics company SIRS-Lab in order to conduct research into sepsis treatment.

The two companies are to collaborate on investigations into molecular diagnostic tests designed to help achieve early and accurate targeting of anti-infective therapy among patients with sepsis and severe fungal bloodstream infections.

Researchers will examine the impact of molecular test diagnoses on clinical outcomes, as well as assessing the pharmacoeconomics of conducting such interventions.

It is hoped that this collaborative effort can help to improve the prognosis of patients affected by life-threatening infections.

Barbara Staehelin, chief executive officer of SIRS-Lab, said: "We are delighted to be working with Pfizer, one of the leaders in anti-infective therapy, and hope that this collaboration will help to improve the outcomes for patients with sepsis."

This comes in the same month that Pfizer announced it will be collaborating with academic medical centres around the world as part of its new Global Centers for Therapeutic Innovation initiative.ADNFCR-8000103-ID-800255894-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.